0001683168-19-000573.txt : 20190307 0001683168-19-000573.hdr.sgml : 20190307 20190307171931 ACCESSION NUMBER: 0001683168-19-000573 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190307 DATE AS OF CHANGE: 20190307 EFFECTIVENESS DATE: 20190307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xenetic Biosciences, Inc. CENTRAL INDEX KEY: 0001534525 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452952962 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-334343 FILM NUMBER: 19666769 BUSINESS ADDRESS: STREET 1: 99 HAYDEN AVENUE, SUITE 230 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-778-7720 MAIL ADDRESS: STREET 1: 99 HAYDEN AVENUE, SUITE 230 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: General Sales & Leasing, Inc. DATE OF NAME CHANGE: 20130227 FORMER COMPANY: FORMER CONFORMED NAME: GENERAL AIRCRAFT INC. DATE OF NAME CHANGE: 20111108 D 1 primary_doc.xml X0708 D LIVE 0001534525 Xenetic Biosciences, Inc. 40 SPEEN STREET, SUITE 102 FRAMINGHAM MA MASSACHUSETTS 01701 781-778-7720 NEVADA None General Sales & Leasing, Inc. GENERAL AIRCRAFT INC. Corporation true Jeffrey Eisenberg 40 Speen Street, Suite 102 Framingham MA MASSACHUSETTS 01701 Executive Officer Director James Callaway 40 Speen Street, Suite 102 Framingham MA MASSACHUSETTS 01701 Director Firdaus Dastoor 40 Speen Street, Suite 102 Framingham MA MASSACHUSETTS 01701 Director Dmitry Genkin 40 Speen Street, Suite 102 Framingham MA MASSACHUSETTS 01701 Director Roman Knyazev 40 Speen Street, Suite 102 Framingham MA MASSACHUSETTS 01701 Director Roger Kornberg 40 Speen Street, Suite 102 Framingham MA MASSACHUSETTS 01701 Director Adam Logal 40 Speen Street, Suite 102 Framingham MA MASSACHUSETTS 01701 Director Curtis Lockshin 40 Speen Street, Suite 102 Framingham MA MASSACHUSETTS 01701 Executive Officer James Parslow 40 Speen Street, Suite 102 Framingham MA MASSACHUSETTS 01701 Executive Officer Biotechnology No Revenues 06b false 2019-03-05 false true true false 0 Maxim Group LLC 12078 None None 405 LEXINGTON AVENUE NEW YORK NY NEW YORK 10174 NY NEW YORK false 3485250 3485250 0 Represents warrants to purchase 1,549,000 shares of common stock with an exercise price of $2.25 per share. false 3 0 216824 The Company completed a concurrent direct registered offering for gross proceeds of $3,097,491. The amount above represents a 7% fee paid in connection with the concurrent direct registered offering pursuant to an engagement agreement. 0 false Xenetic Biosciences, Inc. /s/ James Parslow James Parslow Chief Financial Officer 2019-03-07